Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Retrospective Performance Analyses of over Two Million U.S. QuantiFERON Blood Sample Results

Authors: Bi C, Clark RB, Master R, Kapoor H, Kroll MH, Salm AE, Meyer WA 3rd.

Citation: Microbiol Spectr. 2021 Jul 28:e0009621. doi: 10.1128/Spectrum.00096-21. Online ahead of print.

Specialties: Infectious Disease

Download key summary

Related content

Publication
Elevated Rates of Indeterminate Results on QuantiFERON®-TB Gold Plus in COVID-19 Patients
Conference Presentation
Lower indeterminate rates using single lithium heparin tube blood collection for the QuantiFERON TB Gold Plus QFT Plus test
Test FAQ
QuantiFERON TB Gold Plus
Publication
Performance of the Roche Cobas MTB Assay for the Molecular
Conference Presentation
Automation of Blood Sample Processing for T-SPOT®.TB Assay with Extended Blood Sample Stability: A Validation Study
Conference Presentation
T SPOT TB Assay Using Extended Stored Blood Samples and Alternative Anticoagulant A Validation Study
Test FAQ
T-SPOT®.TB

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.